Overview

Brain Mechanisms and Targeting Insomnia in Major Depression

Status:
Unknown status
Trial end date:
2010-02-01
Target enrollment:
Participant gender:
Summary
Preliminary studies suggest that the response to antidepressant medication can be accelerated by targeting insomnia with adjunctive use of eszopiclone. It is not yet known what mechanism(s) support this acceleration in response, though preliminary findings support the hypothesis that early restoration of sleep may facilitate BDNF-based effects of antidepressant medications. The optimal duration of co-treatment is also unknown. This study will test specific hypotheses about brain mechanisms and evaluate the effects of continued eszopiclone beyond the time window when response acceleration should be observed.
Phase:
Phase 4
Details
Lead Sponsor:
University of California, Los Angeles
Treatments:
Citalopram
Dexetimide
Eszopiclone